Particularly for patients with MCL with high-risk disease profiles, including those with blastoid variants, elevated Ki-67 proliferation indices, TP53 gene mutations or increased protein expression, and disease progression within 24 months of initial diagnosis, the prognosis is generally poor (3). Here, TP53 is linked to mantle cell lymphoma.